The Gallardos’ pharmaceutical company will investigate, together with the German biotechnology company, diseases such as atopic dermatitis and basal cell carcinoma. Disbursements will occur as certain milestones are met.
Almirall continues to lay the foundations for its future growth. In recent months, the Gallardos’ pharmaceutical company has reached several agreements with biotech companies and university centers around the world to strengthen its R&D in early stages. L
5